Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2017 Filed May 5, 2017 22:13 UTC |
Vandebroek Sophie V.Director
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018661 · doc1.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:13 UTC |
Vandebroek Sophie V.Director
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018661 · doc1.xml · derivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,720 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:12 UTC |
Kingsley Lawrence DDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018659 · doc1.xml · derivative · entry 2 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:12 UTC |
Kingsley Lawrence DDirector
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018659 · doc1.xml · derivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:11 UTC |
JUNIUS DANIEL MDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018658 · doc1.xml · derivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:11 UTC |
JUNIUS DANIEL MDirector
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018658 · doc1.xml · derivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,142 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:11 UTC |
HENDERSON REBECCA MDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018657 · doc1.xml · derivative · entry 4 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:11 UTC |
HENDERSON REBECCA MDirector
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018657 · doc1.xml · derivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,094 Underlying: Common Stock · 289 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F5 · price: Not applicable. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:10 UTC |
END WILLIAM TDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018656 · doc1.xml · derivative · entry 2 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:10 UTC |
END WILLIAM TDirector
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018656 · doc1.xml · derivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,094 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:09 UTC |
Claflin Bruce L.Director
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001140361-17-018655 · doc1.xml · derivative · entry 2 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:09 UTC |
Claflin Bruce L.Director
|
GrantDeferred Stock Unit · Derivative | 289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-018655 · doc1.xml · derivative · entry 1 Claflin Bruce L. · CIK 0001403694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307 Underlying: Common Stock · 289 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| April 28, 2017 Filed May 1, 2017 22:03 UTC |
Kingsley Lawrence DDirector
|
GrantCommon Stock | 97 | $167.73 | $16,269.81 |
DisclosureSEC source: 0001140361-17-017678 · doc1.xml · nonDerivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($16,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| April 28, 2017 Filed May 1, 2017 22:02 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 30 | $167.73 | $5,031.90 |
DisclosureSEC source: 0001140361-17-017677 · doc1.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($5,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| April 28, 2017 Filed May 1, 2017 22:02 UTC |
CRAIG THOMASDirector
|
GrantCommon Stock | 43 | $167.73 | $7,212.39 |
DisclosureSEC source: 0001140361-17-017676 · doc1.xml · nonDerivative · entry 1 CRAIG THOMAS · CIK 0001184156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,471 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($7,143.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:01 UTC |
Kingsley Lawrence DDirector
|
PurchaseCommon Stock | 1,000 | $146.48 | $146,480.00 |
DisclosureSEC source: 0001140361-17-010359 · doc1.xml · nonDerivative · entry 1 Kingsley Lawrence D · CIK 0001301427 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,135 Read SEC document |
| February 28, 2017 Filed Mar 6, 2017 23:44 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 300 | $146.00 | $43,800.00 |
DisclosureSEC source: 0001140361-17-010774 · doc1.xml · nonDerivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,950 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $145.95 to a high of $146.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2017 Filed Mar 6, 2017 23:44 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 5,500 | $145.23 | $798,767.75 |
DisclosureSEC source: 0001140361-17-010774 · doc1.xml · nonDerivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,250 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $144.91 to a high of $145.91 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2017 Filed Mar 6, 2017 23:44 UTC |
HENDERSON REBECCA MDirector
|
SaleCommon Stock | 700 | $144.50 | $101,152.94 |
DisclosureSEC source: 0001140361-17-010774 · doc1.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,750 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $143.88 to a high of $144.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 50,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 50,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 2,286 | Not disclosed Strike: $43.71 | Not disclosed |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,286 shares Expires 2019-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 1,143 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2017, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 3,205 | $142.84 | $457,808.29 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,947 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $142.80 to a high of $143.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
SaleCommon Stock | 31,795 | $142.55 | $4,532,326.38 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,152 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.80 to a high of $142.795 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 50,000 | $38.80 | $1,939,750.00 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:12 UTC |
AYERS JONATHAN WDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 2,286 | $43.71 | $99,921.06 |
DisclosureSEC source: 0001140361-17-008884 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:45 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,880 | Not disclosed Strike: $53.19 | Not disclosed |
DisclosureSEC source: 0001140361-17-008416 · doc1.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,760 Underlying: Common Stock · 1,880 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests in five equal annual installments, beginning on January 1, 2015. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:45 UTC |
MCKEON BRIAN PExecutive VP & CFO
|
Exercise / conversionCommon Stock | 1,880 | $53.19 | $99,987.80 |
DisclosureSEC source: 0001140361-17-008416 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:45 UTC |
END WILLIAM TDirector
|
SaleCommon Stock | 5,000 | $141.71 | $708,534.00 |
DisclosureSEC source: 0001140361-17-008415 · doc1.xml · nonDerivative · entry 1 END WILLIAM T · CIK 0001184157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,256 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $141.6166 to a high of $141.8165 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 14 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,868 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 13 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,274 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F9 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 12 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,620 Underlying: Common Stock · 282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 11 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 Underlying: Common Stock · 327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the Stock Split. F9 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 10 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,229 Underlying: Common Stock · 342 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F9 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2013. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
GrantRestricted Stock Unit · Derivative | 1,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 9 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,571 Underlying: Common Stock · 1,059 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F9 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 8 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F9 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 10,386 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · derivative · entry 7 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,386 Underlying: Common Stock · 10,386 shares Expires 2027-02-13 F9 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Tax withholdingCommon Stock | 575 | $141.60 | $81,420.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 6 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,857 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 5 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 4 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 282 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 3 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 327 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 2 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:23 UTC |
TWIGGE GIOVANICORPORATE VICE PRESIDENT
|
Exercise / conversionCommon Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008021 · doc1.xml · nonDerivative · entry 1 TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 8 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,103 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F7 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,509 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F7 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
GrantRestricted Stock Unit · Derivative | 1,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,855 Underlying: Common Stock · 1,059 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F7 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F7 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 10,386 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,386 Underlying: Common Stock · 10,386 shares Expires 2027-02-13 F7 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
Tax withholdingCommon Stock | 273 | $141.60 | $38,656.80 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,496 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC |
Studer JacquelineCVP, Gen. Counsel & Secretary
|
Exercise / conversionCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 43 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.